Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2007 Nov 15;17(22):6326-9. Epub 2007 Sep 2.

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

Author information

1
Cancer and Infection Research, AstraZeneca, Mereside, Alderley Park, Macclesfield, UK.

Abstract

Neutral 5-substituted 4-anilinoquinazolines addressed high in vivo clearance and phospholipidosis associated with previous basic compounds. A representative compound 8a inhibited tumor growth in a mouse xenograft model when co-administered with the cytochrome P450 inhibitor 1-aminobenzotriazole (ABT), and data are consistent with pharmacology primarily reflecting inhibition of erbB2 receptor tyrosine kinase.

PMID:
17869514
DOI:
10.1016/j.bmcl.2007.08.073
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center